No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Sky Labs’ CART-I, a Wearable Heart Monitoring Medical Device

Advances Into the British Medical Device Market

Editor: What To Know

  • In May, Sky Labs signed a contract with Titan Commerce Continental Services GmbH, the largest wearable medical device distributor in Germany, to sell CART-I in Germany, Austria, and Switzerland, based on which Sky Labs will steadily expand its global distribution network.
  • The sharp growth of tele-care, telehealth, and mobile health markets that was triggered by medical digitalization in Britain led to a high level of interest in relevant innovative products which Sky Labs recognized as an opportunity.
  • CART-I garnered the industry's attention when it was adopted early this year for a clinical study conducted ‘to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed' by Professor Timothy Betts, a cardiologist and arrhythmia specialist at Oxford University Hospital.

Sky Labs (CEO: Jack Lee), a global health care start-up, will fully advance into the British medical device market based on ‘CART-I (Cardio Tracker),’ the company’s wearable heart monitoring medical device.

Through its global website Sky Labs announced that it will officially sell CART-I, the world’s first ring-type medical device to monitor heart signals, to consumers in England. CART-I earned CE-MDD medical device approval in Europe, and therefore can be used for atrial fibrillation monitoring and disease diagnoses in Europe. It uses an electrocardiogram (ECG) to help collect more precise cardiac signals when the user feels abnormal symptoms and uses the photoplethysmography (PPG) sensor for continuous atrial fibrillation monitoring without the user’s intervention.

CART-I garnered the industry’s attention when it was adopted early this year for a clinical study conducted ‘to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed’ by Professor Timothy Betts, a cardiologist and arrhythmia specialist at Oxford University Hospital. This enabled Sky Labs to lay the foundation for making inroads into England. The sharp growth of tele-care, telehealth, and mobile health markets that was triggered by medical digitalization in Britain led to a high level of interest in relevant innovative products which Sky Labs recognized as an opportunity.

A user can simply wear CART-I on his or her finger for automatic measuring of atrial fibrillation and heart rate 24/7 without taking any separate action. The heart can be monitored easily in daily life by people who have suffered from AF or have a family history of AF which are leading chronic diseases that are known to have a low diagnosis rate. In accordance with this, not only can the diagnosis rate of atrial fibrillation be increased, but it also provides remote monitoring between the user and health care professionals.

Data that is continually measured through CART-I is transmitted to a cloud platform. The massive amount of data collected is processed into significant data that allows medical judgments by Sky Labs’ in-house developed AI technology and sent to the user’s application and the medical professional’s web. This data helps medical professionals make an accurate diagnosis.

Jack Lee, CEO of Sky Labs, said, “There is an emergence of the need to remote monitor chronic diseases all across the globe. Against this backdrop, CART-I is a product that can satisfy the needs of both patients and medical professionals. Beginning with its entry into Britain, which has the world’s most advanced systems in patient-centered treatment, Sky Labs will continually enhance its global competitiveness.”

On the occasion of product sales in Britain, Sky Labs will carry out its first discount promotion. A £50 discount will be applied for customers who purchase CART-I by November 30. Purchases can be made on the website.

Sky Labs is recognized as a health care start-up with technological prowess in Europe. It became the only Korean company to win the Digital Health & Technology Competition of the European Society of Cardiology (ESC) for two consecutive years and to be chosen as the Technology Pioneer at the World Economic Forum 2019.

In May, Sky Labs signed a contract with Titan Commerce Continental Services GmbH, the largest wearable medical device distributor in Germany, to sell CART-I in Germany, Austria, and Switzerland, based on which Sky Labs will steadily expand its global distribution network.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy